Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ropeginterferon |
Synonyms | |
Therapy Description |
Ropeginterferon is polyethylene glycol (PEG)-conjugated recombinant interferon alpha, subtype 2b, which may result in reduced tumor cell proliferation and colony growth (PMID: 30287855). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ropeginterferon | RopegInterferon alpha-2b|Ropeg|Besremi | Ropeginterferon is polyethylene glycol (PEG)-conjugated recombinant interferon alpha, subtype 2b, which may result in reduced tumor cell proliferation and colony growth (PMID: 30287855). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | acute megakaryocytic leukemia | sensitive | Ropeginterferon | Preclinical - Cell culture | Actionable | In a preclinical study, a megakaryoblastic leukemia cell line expressing JAK2 V617F demonstrated inhibition of cell proliferation in culture when treated with Ropeginterferon (PMID: 30287855). | 30287855 |
JAK2 V617F | myeloproliferative neoplasm | sensitive | Ropeginterferon | Preclinical - Cell culture | Actionable | In a preclinical study, Ropeginterferon treatment resulted in dose-dependent inhibition of cell proliferation in myeloproliferative neoplasm cell lines harboring JAK2 V617F in culture (PMID: 30287855). | 30287855 |
JAK2 V617F | polycythemia vera | sensitive | Ropeginterferon | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived erythroid progenitors harboring JAK2 V617F demonstrated sensitivity to Ropeginterferon in culture (PMID: 30287855). | 30287855 |
JAK2 V617F | polycythemia vera | sensitive | Ropeginterferon | Clinical Study - Cohort | Actionable | In a clinical study using data from a Phase III trial, polycythemia vera patients demonstrated significant reduction in the median JAK2 V617F mutational burden at 12 months following treatment with Ropeginterferon compared to Droxia (hydroxyurea) (13.8% vs. 33.2%; p<0.02) (PMID: 30287855; NCT01949805). | 30287855 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05481151 | Phase III | Ropeginterferon | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Active, not recruiting | USA | CAN | 0 |